Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial

BACKGROUND: The primary aim of this trial was to determine the recommended phase II dose (RP2D) of weekly paclitaxel (wP) administered in combination with oral metronomic cyclophosphamide (OMC). METHODS: Patients ≥ 18 years of age with refractory metastatic cancers were eligible if no standard curat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Pannier, Diane, Adenis, Antoine, Bogart, Emilie, Dansin, Eric, Clisant-Delaine, Stéphanie, Decoupigny, Emilie, Lesoin, Anne, Amela, Eric, Ducornet, Sandrine, Meurant, Jean-Pierre, Le Deley, Marie-Cécile, Penel, Nicolas
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6069824/
https://ncbi.nlm.nih.gov/pubmed/30064401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4678-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi